Euroimmun Medizinische Labordiagnostika Ag

Mayo Foundation for Medical Education and Research

Euroimmun Medizinishe Labordiagnostika Ag

Lars Komorowski

Christian Probst

Yvonne Denno

Ramona Miske

Madeleine Scharf

Winfried Stoecker

Winfried Stöcker

Inga-Madeleine Dettmann

Stephanie Kade

Stefanie Hahn

Christiane Radzimski

Wolfgang Schlumberger

Anthonina Janssen

Vanda A Lennon

Thomas J Kryzer

Andrew McKeon

Sean J Pittock

Katja Steinhagen

Iswariya Venkataraman

Josephe A Honorat

Cornelia Dähnrich

Sven Meuth

Mandy Unger

Bianca Teegen

Ralf Gieß

Detlef Zillikens

Thomas Mothes

Christoph Hammers

Enno Schmidt

Stephanie Goletz

Fedor Heidenreich

Heinz Wiendl

Nico Melzer

George Trendelenburg

Farid Benkhadra

Winfried STÖCKER

Marcel Hinkelammert

Kathrin Baumert

Matthias Theuser

Mareike Holste

Antje Dammermann

Cornelia DÄHNRICH

Stephan Tiede

Fedor ProfDr Heidenreich

A method for diagnosing a disease can include detecting, in a sample from a patient, an autoantibody binding to Septin-7. A polypeptide comprising Septin-7 or a variant thereof can be used for the diagnosis of a disease. Preferably, the polypeptide is used to detect an autoantibody binding to Septin-7 in a sample. A kit is useful for the diagnosis of a disease. The kit may include a polypeptide that includes Septin-7 or a variant thereof or a medical device that includes a polypeptide that includes Septin-7 or a variant thereof and an autoantibody to Septin-7.

Autoantibodies to Septin-7 and diagnosis of neurological disease

The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a polypeptide comprising a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, or a variant thereof, a use of said polypeptide for the diagnosis of a disease, an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a use of the autoantibody for the diagnosis of a disease, a method for isolating an autoantibody binding to a polypeptide selected from the group comprising NSF, STX1B, DNM1 and VAMP2, a pharmaceutical composition or medical device comprising said polypeptide according to the present invention, a kit for the diagnosis of a disease comprising said polypeptide or said medical device and a use of said polypeptide or autoantibody for the manufacture of a kit or medical device.

Diagnosis of a neuroautoimmune disease

A polypeptide contains laminin beta-4 and a carrier contains the polypeptide. An antibody, preferably autoantibody, is against laminin beta-4. Furthermore, use of the polypeptide, carrier or autoantibody for the diagnosis of a disease, and a method with the step of detecting an autoantibody against laminin beta-4 in a sample are described.

Diagnosis of blistering autoimmune disease

The present invention relates to a method for diagnosing a disease, comprising the step detecting in a sample an autoantibody binding to the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase, a use of a membrane-associated human Na(+)/K(+) ATPase or a variant thereof for the diagnosis of a disease, an isolated and/or recombinant polypeptide comprising the alpha 3 subunit of the human neuronal Na(+)/K(+) ATPase or a variant thereof, for use in the treatment of a disease, an autoantibody binding to said polypeptide and a method for isolating such autoantibody, a pharmaceutical composition, medical or diagnostic device or test kit comprising the polypeptide.

Diagnosis of a neurological disease

A method is used for diagnosing a disease by detecting in a sample with antibodies from a patient an autoantibody binding to DAGLA.

The present invention relates to a method for diagnosing a disease comprising the step detecting in a sample comprising antibodies from a patient and also antibody binding to RGS8, a method for diagnosing a disease comprising the step detecting in a sample from a patient the level or activity of RGS8, a polypeptide comprising RGS8 or a variant thereof, a use of set polypeptide for the diagnosis of a disease, an antibody binding to RGS8, a use of the antibody for the diagnosis of the disease, a method for isolating an autoantibody binding to RGS8, a pharmaceutical composition or medical device comprising the polypeptide according to the present invention, a kit for the diagnosis of a disease comprising the polypeptide or the medical device according to the present invention and a use of the polypeptide, the antibody or the antibody for the manufacture of a kit or medical device.

A method for diagnosing a disease by detecting an autoantibody that binds to flotillin1 and/or flotillin2 in a sample, a polypeptide comprising flotillin1 and/or flotillin2 or a variant thereof, which may be immobilized, a method of treating a disease by applying to a subject the polypeptide that binds to an autoantibody, an autoantibody binding to flotillin1 and/or flotillin2, a method for isolating the autoantibody, a pharmaceutical composition, a medical device and test kit comprising the polypeptide, are provided. A method for detecting the presence of an autoantibody is also provided.

Diagnosis of a neuroautoimmune disease comprising measuring autoantibodies to flotillin1 and/or flotillin2

Polypeptides including Neurochondrin and autoantibodies binding to polypeptides including Neurochondrin are provided. Methods for diagnosing or treating diseases associated with neurological symptoms or cancers are also provided. The methods of diagnosis may include detecting an autoantibody binding to Neurochondrin in a sample from a patient. The methods of treatment may include administering a polypeptide comprising Neurochondrin to a patient.

Detection of anti-neurochondrin autoantibody in patients with cerebellar ataxia or cerebellitis

The present disclosure relates to proteins derived from OspC from bacteria of the genus, in particular a protein which comprises a first OspC polypeptide, wherein the first OspC polypeptide is linked to a second OspC polypeptide via a disulphide bridge. The disclosure also relates to a method for the detection of antibodies against OspC and a method for the detection of ainfection, wherein a protein according to the disclosure is employed, and also to a diagnostic kit and a vaccine against

Polypeptides and methods for the specific detection of antibodies in patients with a borrelia infection

[object Object]

The present invention relates to fusion peptides that are derived from components of gliadin, to a method and reagents for the serological diagnosis of celiac disease or dermatitis herpetiformis by way of assaying antibodies that are directed against modified gliadin. The invention also relates to methods and pharmaceutical compositions for treating said diseases by specific immunoabsorption of these antibodies.

Method and immunoabsorbents for specific detection and absorption of antibodies associated with celiac disease and dermatitis herpetiformis

Growing community of inventors

Ratzeburg, Germany

Lars Komorowski